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Value judgment of health interventions 
from different perspectives: arguments 
and criteria
Karin M. Vermeulen* and Paul F. M. Krabbe
Abstract 
Background: The healthcare sector is evolving while life expectancy is increasing. These trends put greater pres-
sure on healthcare resources, prompt healthcare reforms, and demand transparent arguments and criteria to assess 
the overall value of health interventions. There is no consensus on the core criteria by which to value and prioritize 
interventions, and individual stakeholders might value specific elements differently. The present study is based on a 
literature review that retrieved the most widely recognized arguments and criteria used in decision-making. The aim 
was to compile a smaller set of arguments and criteria that would seem most relevant to different stakeholders.
Methods: A literature review was performed in Medline and EMBASE. The initial search retrieved over 2000 articles 
and documents of relevant committees. A selection was made based on their reference to healthcare, policy issues, or 
social justice. Finally, 84 papers were included. Data extraction took place after appraisal of the articles. A full table was 
made, including all arguments and criteria found; next, identical or largely overlapping arguments were excluded. The 
remaining arguments and criteria were assessed for relevance and a reduced set was compiled.
Results: The final set included 25 arguments and criteria, categorized by type (clinical, social justice, ethical, and 
policy). For each argument and criterion, relevance to stakeholders was scored on three levels (not, partly, and com-
pletely relevant).
Conclusions: Many arguments and criteria play a role in making value judgments on health interventions, but not 
all are relevant to all interventions. Moreover, they may interact with each other. A viable way to deal with interacting 
and possibly conflicting arguments and criteria might be to arrange public discussions that would evoke different 
stakeholders’ perspectives.
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Background
Due to ongoing advances in medicine and health technol-
ogy and the broadening scope of health services, health 
systems face the challenge of prioritizing new technolo-
gies [1, 2]. Furthermore, as life expectancy increases, the 
proportion of the elderly will continue to grow, though 
they may not age in good health [3, 4]. The additional 
burden these trends place on healthcare resources, 
explains why many national health systems have recently 
introduced reforms [5]. All assessments performed for 
healthcare systems and all reimbursement decisions for 
new health technologies depend on an assessment of 
benefits or value [6, 7]. To ascertain this value requires an 
explicit framework defining the goals of a health system 
against which outcomes can be judged and performance 
quantified [8].
In the UK, the National Institute for health and Clinical 
Excellence (NICE) has four guidance programs. ‘Tech-
nology appraisals’ and ‘Clinical guidelines’ take the clini-
cal effectiveness and cost-effectiveness of an intervention 
into account. Under the program ‘Interventional proce-
dures’, clinical efficacy and safety of the intervention are 
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taken into account, whereas cost-effectiveness is not. 
‘Public health’ takes effectiveness and cost-effectiveness 
of public health activities into account [9, 10].
In the Netherlands, a more elaborate framework is 
applied. The Minister of Health, following advice from 
governmental organizations (e.g., National Health-
care Institute (Zorginstituut Nederland; formerly called 
Health Insurance Board, CVZ), decides which interven-
tions are to be covered by health insurance. Since the 
1990s, the so-called Dunning criteria have been used to 
formulate this advice [11]. Currently, the four principal 
criteria are need, effectiveness, cost-effectiveness, and 
feasibility [12, 13].
According to the Belgian Drug Reimbursement Com-
mittee, an application for reimbursement is needed for 
Class 1 drugs, i.e. those with more therapeutic value than 
the existing alternatives. The decision on reimbursement 
is based on multiple factors, including the therapeu-
tic value of the drug, its price, its importance in clinical 
practice, its budget impact, and cost-effectiveness [14].
On a global level, the World Health Organization 
(WHO) mentions three ethical principles for prioritizing: 
efficiency (maximizing population health), fairness (min-
imizing health differences), and utility (greatest good for 
the greatest number) [15].
Many national and individual studies have examined 
the methods and principles underpinning the assessment 
of health interventions [6, 16–20]. Overall, results of 
these studies suggest heterogeneity of the identified crite-
ria [17], convergence among decision-makers on the rele-
vance of criteria [20], and divergent operationalization of 
(the same) criteria [17]. It has been suggested that some 
of the discrepancies found are strongly related to contex-
tual factors [20]. Thus, there is no consensus on the core 
criteria by which to value health interventions, and some 
authors even assert that the fundamental principles are 
poorly defined [21–23]. According to Golan [2], the key 
to evaluating the success of prioritization efforts lies in 
articulating appropriate principles as well as formulating 
reasons that are grounded in clear value choices [24].
Apart from these fundamental concerns, the valua-
tion of interventions and the relevance of criteria might 
differ depending on who is the ‘judge’ (clinicians, health 
authorities, general population, or patients). Different 
stakeholders might value different determinants that 
could affect coverage decisions in different ways. In addi-
tion, the growing involvement of patients in healthcare is 
a factor in policy-making.
The aim of the present study is to identify the most 
widely recognized arguments and criteria that are used 
in making decisions about patient treatments or in pri-
oritizing health interventions. Arguments and criteria are 
hard to define. Some elements can be clearly regarded as 
criteria, and others as arguments, but there is also quite 
some overlap between the two. Criteria are considered 
here as a rule or principle that has to be met or a stand-
ard by which one judges, whereas an argument refers to 
a way of reasoning (group of statements) to be in favor 
for something or not. We intend to identify and summa-
rize the most salient ones, to inform a broad audience of 
policy makers and health care professionals.
Methods
Search strategy
An electronic search was performed in the Medline and 
EMBASE databases (February 2018). Since our aim was 
to identify and summarize the most salient arguments 
and criteria, to inform a broad audience, a review of the 
literature was carried out, instead of a systematic review. 
A literature review can cover a wide range of subjects at 
different levels of completeness and comprehensiveness. 
[NCBI] Search terms were related to priority-setting, 
decision-making, decision tools, and resource alloca-
tion. Logical combinations were made with the following 
perspectives: patient, healthcare professional, clinician, 
decision-maker, health authorities, and general public/
population. After the initial search, further refinements 
were made in light of expert opinion (KV, PK).
The initial search retrieved over 2000 articles, of which 
a selection was made on the basis of their reference to 
healthcare, policy issues, or social justice. The references 
in these articles were searched and additional papers 
(about 10) were included. Then five policy documents 
relating to social value judgment and economic evalua-
tion methodology were found on websites and added to 
the set. Ultimately, 84 documents were included in the 
review.
Procedure
After performing the search, the articles were examined 
to discern which arguments and criteria they concerned. 
A table was made containing all of the arguments and 
criteria mentioned. The next step was to exclude identi-
cal and largely overlapping arguments. Finally, using the 
same procedure, the remaining arguments and criteria 
were assessed for relevance.
Results
After retrieval of all the different arguments and crite-
ria that were used or put forward in the identified lit-
erature, we observed that most of these can be assigned 
to four broad categories: clinical, social justice, ethi-
cal, and policy. ‘Clinical’ denotes all those issues that 
arise in daily practice when medical service is offered 
to patients. ‘Social justice’ (or distributive justice) con-
cerns issues raised outside medical practice, namely in 
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the interdisciplinary field of political science and politi-
cal philosophy. The term generally refers to a set of insti-
tutions that enable people to lead a fulfilling life and be 
active contributors to their community. Such arrange-
ments fall under entities dealing with (international) 
law, public services, labor rights, regulation of markets, 
and healthcare. Pursuit of social justice is laudable, but 
medical doctors, academics, and patients face the sober-
ing reality of limited resources and the need to devote 
tax revenues to other important sectors (e.g., education, 
military, social security). Ethical issues are mainly com-
mented on by clinicians, politicians, journalists, and phi-
losophers, and supervised by the latter. Arguments raised 
in this discourse mainly concern individuals and less 
groups of patients (i.e., social justice, priority setting). 
Many are specific and have a narrow focus (e.g., end-of-
life decisions, dignity). Most politicians have a political 
view that comprises specific considerations related to 
social justice and ethical issues, which have to be molded 
into a ‘compromise’ for finding effective support from 
other politicians and the public. Overall, policy issues are 
aligned with efforts to keep things manageable and under 
control, while the clinicians are mainly concerned with 
doing their best for their patients.
Some of the arguments and criteria can play a role in 
multiple categories. For example, ‘Rule of Rescue can be 
regarded as a clinical issue, but it can also be seen as an 
ethical aspect. Therefore, our schematic representation 
should not be regarded as absolute (Fig. 1).
Clinical issues
Clinical issues, health benefits, or health outcomes tradi-
tionally play an important role in many healthcare deci-
sion-making procedures. While the terminology varies 
widely, the decision criteria of most healthcare systems 
explicitly include the health outcomes and benefits of an 
intervention. Some arguments refer to these directly; oth-
ers mention the health status or demographic character-
istics of the individual or size of the targeted population 
[25]; and one argument can also be seen as a principle 
(Rule of Rescue) [23, 26].
Longevity
Longevity can be seen as a characteristic of health gain 
[25]. ‘Life-saving’ or life-extending procedures are highly 
valued, significantly more highly than care interventions. 
There is a heroic element in the act of life-saving, and it 
has traditionally been one of the main things expected of 
physicians (see also: Rule of Rescue).
Health status
The assessment of medical interventions and health-
care services also takes ‘health status’ or ‘quality of life’ 
into account. These measures are relevant because, ulti-
mately, the goal of all health interventions is to improve 
the patient’s perceived health condition. Health status 
reflects an individual’s relative level of wellness and ill-
ness, taking into account the presence of biological or 
physiological dysfunction, symptoms, and functional 
impairment. Most measures of health status include key 
indicators such as physical function, sensation, self-care, 
cognition, pain, and discomfort [27].
Effectiveness
The criteria mentioned under the heading of ‘effective-
ness’ or clinical benefit include the following: general 
benefits, effect on mortality, efficacy, safety, adverse 
effects, adherence, effect on longevity, and effect on 
health status (i.e., quality of life), and number in need of 
treatment. In that sense, effectiveness captures several 
of the distinct criteria that are classified here as ‘clinical’. 
Individual health benefits strongly influence policy deci-
sions in various countries [28]. The number of patients 
in ‘need of treatment’ adds information to the decision 
about the likelihood that a population will benefit from a 
medication or intervention [29, 30].
Time until benefit
‘Time until benefit’ is tied to the judgment of whether a 
patient’s life expectancy is long enough to benefit from 
the intervention. Medication for symptom relief, such as 
analgetics, may show benefits in a short time and would 
continue to benefit all patients, including those close to 
death. Medications used for prevention may have a time 
until benefit of years. Unlike the number needed to treat, 
which adds information about the population that will 
benefit, the notion of time until benefit may be useful in 
discussions on individual patients as well [29]. From a 
patient’s perspective, the question ‘when will it help?’ is 
often just as important as the question ‘how much will it 
help?’ From a professional’s viewpoint, looking at the bal-
ance between an older patient’s life expectancy and the 
lag in time to benefit might help clinicians identify which 
patients are more likely to be helped and which ones are 
more likely to be harmed by the intervention [31].
Rule of Rescue
Tension sometimes arises between the injunction to do as 
much good as possible, and the injunction to rescue iden-
tifiable individuals in immediate peril, regardless of costs. 
This is called the ‘Rule of Rescue’ [23, 26]. The principle 
was named by Jonsen in 1986 [32] in a paper describing 
our practical incompetence to deal with life-saving or 
life-sustaining technologies. Our moral response to the 
imminence of death demands that we rescue the doomed 
[33]. As such, the Rule of Rescue can also be seen as an 
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Fig. 1 Arguments and criteria for resource allocation categorized into four domains and indications of the relevance of these arguments and crite-
ria to different stakeholders (open circle = not important, half open circle = some importance, closed circle = important)
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Kantian ethical imperative and inherent ethical phenom-
enon. One of the most conspicuous features of this rule, 
according to McKie, is the tendency to disregard oppor-
tunity costs (benefits or values of something that must be 
given up to acquire or achieve something else) when an 
identifiable individual is visibly threatened [34]. There is a 
tendency to act first and consider the costs later.
Age
In many countries there is a strict (ethical) limitation 
to considering age as a criterion in decision-making on 
non-preventive medical treatments. Preventive health 
care aims to delay the onset of illness and disease and 
to prevent untimely and premature deaths [35]. In many 
guidelines, age is the main criterion for recommend-
ing preventive interventions. Nevertheless, in recent 
years concerns about equity of access to treatments have 
focused on ageism. As a result, preventive interventions 
are encouraged regardless of age, although this can be 
harmful to the patient and expensive for the health ser-
vice. Yet in many situations, age (or life expectancy) can 
be a good predictor of success [31]. Also, there is increas-
ing awareness that at a certain age, when frailty becomes 
prominent, many medical interventions lose their effec-
tiveness and may even be considered inappropriate.
User‑friendliness
‘User-friendliness’ (convenience) is often seen as an 
aspect of therapeutic value, as it may result into better 
adherence in the case of drugs. Thus, relevant for both 
patient in terms of clinical outcomes, as well as for the 
prescriber, this issue is not often mentioned as a criterion 
by decision makers.
Social justice
‘Social justice’ is the ability to realize one’s potential in 
the society one lives in. It generally refers to a set of insti-
tutions that enable people to lead a fulfilling life and be 
active contributors to their community. Thus, its goal 
amounts to human development, and the relevant insti-
tutions are usually taken to include education, healthcare, 
social security, labor rights, as well as a broader system 
of public services, progressive taxation, and regulation of 
markets. All these constituents are obligated to ensure a 
fair distribution of wealth, equality of opportunity, and 
no gross inequality of outcome [35, 36]. Social justice 
is closely related to distributive justice; the latter means 
ensuring that individuals have both fulfilled their societal 
roles and received what was due to them from society. 
Distributive justice concerns the nature of a socially just 
allocation of goods (e.g., medical treatments) in a soci-
ety. This subject has been given considerable attention 
in philosophy and the social sciences (e.g., psychology, 
economics) [37]. Inextricably connected to social justice 
are themes of values and ethics (see: below).
Need
‘Need’ reflects an impairment relative to a ‘normal’ health 
status. The term must also incorporate a patient’s capac-
ity to benefit from treatment [21, 38], usually expressed 
as the effectiveness or appropriateness of an intervention 
[2, 38]. Healthcare systems include need-based princi-
ples, such as the severity of the condition (the Nether-
lands, Sweden, Norway, Denmark, and France) [2], the 
degree of clinical need (NICE) [9], or the importance of 
human disabilities (Australia) [39]. As such, one of the 
key principles of justice raised in academic discussions 
(alongside maximizing and egalitarian principles, which 
are utilized in the field of economics [40]) is need.
Rawls’ difference principle
A well-known theory of social justice forms the core of 
a work on political philosophy and ethics by John Rawls. 
Originally published in 1971 [41], it was revised in 1975 
and again in 1999. Rawls attempted to solve the prob-
lem of distributive justice. He analyzed the principles of 
justice that would be adopted by rational self-interested 
people whose ‘initial situation’ is characterized by a ‘veil 
of ignorance’ that conceals all factors relevant to the 
determination of their individual fortunes in society [42]. 
The second of these is the ‘difference principle’. Policies 
and structures are to be arranged to diminish social and 
economic (hence: health) inequalities and benefit the 
least-advantaged members of society. Although his work 
is one of the cornerstones of political science, other more 
detailed arguments have been raised dealing with social 
justice in the context of health (Fig. 2).
Fair innings
The ‘fair innings’ approach centers on the feeling that 
everybody in Western countries is entitled to a ‘normal’ 
number of life years. This argument is also part of the 
disability-adjusted life year (DALY) approach used by the 
WHO [43]. The concept of fair innings was introduced 
in the field of health economics and political philoso-
phy by the British economist Alan Williams, although it 
grew from earlier roots [44, 45]. Williams proposed that 
life years gained by people facing less than fair innings 
should be valued more highly than life years gained by 
people expecting to have fair innings or better.
Proportional shortfall
‘Proportional shortfall’ poses that priority should be 
determined by the proportion of quality-adjusted life 
years (QALY) that people lose relative to their remaining 
life expectancy due to some illness. Proportional shortfall 
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compares individuals in relative terms to determine who 
is worse off [46]. Thus, this equity concept combines ele-
ments of the two principles mentioned above. Empirical 
studies based on hypothetical scenarios found that peo-
ple’s preferences were most in line with the fair innings 
arguments, followed by the proportional shortfall prin-
ciple, and then the severity-of-illness or disease severity 
criterion (see below) [47, 48].
Disease severity
In many European countries, such as Norway, Sweden, 
France, Germany, and Spain, reimbursement decisions 
are informed by considerations of severity [49]. Society’s 
appreciation of medical interventions rises sharply with 
the increasing severity of the patients’ condition or health 
status. This criterion is often referred to as a ‘concern for 
the worse-off’ or ‘disease severity’. The severity approach 
is drawn from a number of well-known theories of dis-
tributive justice asserting that the worst-off in society 
have special and legitimate claims [41, 49–51]. It is, how-
ever, not always clear what is meant by severity, and who 
the worst-off are. We may try to rank patients that are 
worse-off with regard to their health status and relate this 
ranking to how much they are helped by treatment [52]. 
Yet there are different ways of approaching this. First, one 
can look at current health status and expected improve-
ment. From this angle, an improvement has more value 
if the current health status is worse but the expected 
improvements are the same [53]. A second approach also 
considers the patient’s past health status.
Fig. 2 Schematic representation of three principal distributive mechanisms as part of social justice considerations (areas are representing health 
status and life years)
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No effective alternative
When a new beneficial treatment is introduced for which 
treatment was previously unavailable, the standard effi-
cacy and cost-effectiveness thresholds are often leveraged 
in order to give this class of patients at least the opportu-
nity to relieve their health condition and to avoid block-
ing innovation of potential treatment options in this area. 
A number of papers report on the preferences for availa-
bility of alternative treatment and all found that a disease 
with no alternative treatment was given priority [54–56]. 
More or less the same train of thought can be observed 
for so-called orphan drugs. Pharmaceutical companies 
develop these for rare diseases and often have no interest 
in producing them from a business perspective. Despite 
not qualifying as cost-effective, many orphan drugs are 
subsidized in the EU member states [57]. The rationale 
for less strict reimbursement thresholds is that the lim-
ited production of these drugs justifies their high price. 
Another argument is that very expensive new drugs or 
treatments should not be withheld from patients if no 
effective alternative treatment is available.
Socio‑economic status
Seldom is ‘socio-economic status’ mentioned as an inde-
pendent criterion for prioritization. It relates to the prin-
ciple of fair innings, which assumes that patients are 
entitled to their expected number of life years [44, 45, 58]. 
It is also related to life expectancy, in that patients with 
a lower socio-economic status are less likely to achieve 
their ‘fair innings’ than patients with a higher one. Thus, 
programs that generate health effects predominantly in 
patients with low socio-economic status would be prefer-
able on the grounds of equity considerations [59].
Ethics
Moral issues embrace various ethical concepts such 
as human dignity, religious or cultural values and con-
victions, but also the question whether a new medical 
intervention is subject to criticism for medicalization, 
overdiagnosis, or overtreatment. Medical ethics (or bio-
ethics, health ethics) emphasis the rights of individuals, 
often the doctor-patient relationship. Less attention is 
given to the institutional and societal implications [60]. 
Many of these more population based moral considera-
tions are addressed in the context of policy science, polit-
ical philosophy, economics and other special disciplines, 
but can be classified as moral too (see: Social justice).
Moral, cultural, and religious values
Hofmann [61] provides an apt overview of morally rel-
evant questions with respect to assessing health technol-
ogy. Moral challenges may be posed by the involvement 
of third parties such as (organ) donors, bio-bank 
contributors, proxies, surrogacy (e.g., donation), and 
family members (in the case of genetic diagnostic testing) 
[61].
Practices that may challenge ‘cultural or religious con-
victions’ are, for example, blood transfusions, which 
Jehovah’s Witnesses refuse to accept, and vaccination, 
which is unacceptable to the (Dutch) orthodox protes-
tant community [62]. Reimbursement decisions related 
to such interventions are valued differently by differ-
ent groups, based on their spiritual beliefs. Niezen [63] 
claims that in dealing with the abstract reports on cost-
effectiveness and need (severity of illness), the Dutch 
committee for appraising medicines ACP puts the person 
who is ill at the center of the appraisal.
Dignity
Care systems, traditions, and philosophies have arisen 
because individual human beings have been considered 
so valuable that they cannot just be left at the mercy of 
their sickness and suffering [64]. Dignity becomes par-
ticularly relevant when medicine has less to offer to 
patients or when people become very old and fragile. In 
that case, the emphasis shifts from cure to care. Espe-
cially for elderly, handicapped, and mentally disabled 
people, it is the tradition of ‘care’ that matters most.
End of life
‘End of life’ care, in its narrow sense, is healthcare for 
patients in the final hours or days of their lives. However, 
the concept also applies more broadly, covering care of 
those with terminal illness that is advanced, progressive, 
and incurable. Management of symptoms plays an impor-
tant part in this type of care. Regarding decision-making 
on coverage, a prime example of dilemmas relating to end 
of life is cancer care. For advanced cancer, difficult trade-
offs must be made between the limited health benefits of 
the drugs and their high cost [65].
Medicalization
‘Medicalization’ is the process whereby social issues, or 
issues related to well-being, are looked at from a medical 
point of view. Development of new tests and medicines 
can increase the risk of medicalization or change the per-
ception of disease. For example, IVF turned a social mat-
ter (childlessness) into a medical one (infertility) [61].
Policy objectives
Governments, health authorities, and other formal insti-
tutions consider a variety of policies regarding national 
health systems. Of course, these institutions also con-
sider the overall values that were discussed above. Apart 
from these there are numerous criteria that policy-mak-
ers typically deal with.
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Public health value
In many European countries, the two main objectives of 
publicly funded healthcare are to maximize population 
health and to reduce inequality in health across groups 
within the population. Both objectives are subject to 
resource constraints and together they constitute ‘public 
health value’. A socio-political target such as well-being 
and a favorable economic condition such as high pro-
ductivity are more easily attained in a nation of healthy 
people. Part of the public health value consists of medical 
interventions that are considered valuable, not so much 
for the individual but for society at large (e.g., infectious 
diseases).
Public pressure
In an Australian study, decision-makers were asked to 
identify factors that influence resource allocation in 
healthcare [66]. Political factors were mentioned most 
frequently. Among others, one important element of 
these political factors was the climate of opinion in soci-
ety and pressure groups. The effect of pressure groups 
or ‘public pressure’ in general may have great impact on 
actual healthcare allocation decisions [67].
Costs
‘Costs’ of healthcare rose rapidly after the Second World 
War in all developed countries. Many reasons can be put 
forward to explain this process: more technical options 
(e.g., CT scan, transplantation); expansion of the con-
tent of healthcare; side-effect of the merits of modern 
healthcare (e.g., people live longer without fatal diseases 
but need more care); professionalization. In combination, 
these factors are responsible for a substantial proportion 
of government spending. This has caused the need for 
policy makers to weigh up the costs to the health system 
of funding an intervention balanced with the effect [68].
Cost‑effectiveness
‘Cost-effectiveness’ is an important criterion in many 
countries [28, 68–71]. It is also called a ‘higher order 
criterion’ since it is a composite measure of costs and 
effects. The effects are often expressed in terms of 
quality-adjusted life years (QALYs). A QALY combines 
(expected) survival with (expected) level of health status 
in a single metric [72]. In the Netherlands, cost-effective-
ness is an important criterion but no absolute threshold 
is applied. Only the legitimacy of the cost-effectiveness 
ratio is assessed [73]. Strict thresholds are rarely set or 
applied in other healthcare systems [17]. For the last 
two decades, the ratio of $50,000 per QALY gained has 
played an enigmatic role as a benchmark for the value 
of care [74]. It seems that certain factors may lead to 
higher acceptable costs per QALY gained, for example, 
in the case of rare diseases (see also: no effective treat-
ment). Alglucosidase alfa (Myozyme), for example, a 
drug used in the treatment of Pompe’s disease [75], was 
only accepted for reimbursement in the Netherlands 
after public discussion and price negotiations with the 
manufacturers.
Budgetary impact
Budgetary impact analysis estimates the financial conse-
quences of adoption and diffusion of a new drug or inter-
vention in a specific healthcare setting such as a hospital 
or clinic or by a private or public insurer [76]. In par-
ticular, such analyses predict how a change in the mix of 
drugs and other therapies will impact spending on that 
condition. The reference point for this analysis is the cur-
rent mix of interventions for the population in question. 
For instance, reading glasses were not accepted for reim-
bursement at a certain stage in the appraisal process due 
to the high budgetary impact of this health aid [13].
Feasibility
One of the criteria used to appraise a new intervention 
is ‘feasibility’ [77]. This criterion is considered a contex-
tual factor and can be evaluated in terms of the available 
means, such as budget, administrative burden, staff and 
ward availability, and expertise. Feasibility is also weighed 
in light of establishing a precedent and other unintended 
effects, but also in view of laws and legislation.
Own responsibility
The overall conception is that each individual is pre-
sumed to be responsible for some aspects of his or her 
health status. Medical doctors are offering their patients 
the best available treatment, taking no consideration 
whether the cause of the injury or disease is related to 
unhealthy lifestyle factors or not. Such lifestyle factors 
related to unhealthy lifestyle are eating habits, smok-
ing, and even performing extreme sports or excessive 
sunbathing [78]. In most health care systems unhealthy 
lifestyle factors are not entered in priority setting. In 
general, the question of own responsibility is a sensitive 
one and has a prominent place in ethics (autonomy). A 
public debate could promote acceptance of decisions on 
resource allocation in which a person’s ´own responsibil-
ity´ and lifestyle factors may have an impact [79]. Objec-
tions to public involvement in the discussion are based 
partly on the assumption that individuals are both sub-
jective and inadequately informed and therefore cannot 
represent the interests of others [79]. But as a German 
study demonstrates, engaging in behavior that is harmful 
to one’s health is generally accepted as a criterion for pri-
oritizing patients, mostly regardless of self-interest [78].
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Discussion
The aim of the present study was to retrieve the most 
generally recognized arguments and criteria that are used 
in healthcare decisions. We got the impression that val-
ues such as those expressed in social justice arguments 
are the leading principles. Although subjective, we have 
attempted to express the level of relevance of the various 
arguments and criteria by four groups: clinicians, health 
authorities, the general population, and patients.
First of all, there are obvious differences between the 
four groups. Clinicians and other health professionals 
predominantly apply clinical arguments in their treat-
ment decisions. Health authorities do take great interest 
in policy arguments and also incorporate social justice 
arguments and clinical criteria in their deliberations. For 
the general population, the picture is less clear. Apart 
from some key criteria such as longevity, health status, 
and ethical concerns for the elderly (dignity, end of life), 
none of the four broad categories: (clinical, social justice, 
ethical, and policy) seems to predominate. Among the 
general population we also observe a moderate interest 
in social justice criteria. Finally, patients are fairly com-
parable to the general population, though they seem less 
interested in social justice arguments.
We identified almost 30 arguments and criteria that 
are relevant and current. Many others were observed but 
not mentioned in our overview, because we regard them 
as either very specific, different names for another con-
cept, or overlapping with another argument or criterion. 
Examples of such redundancies are the following: timely 
deliveries, dosages available, years on market, producer’s 
reputation, and constitutional factor.
Different stakeholders have different interests and 
therefore use different frameworks in their reflections. 
The perspective of clinicians is to bring the best care to 
individual patients. Social justice arguments are deemed 
relevant from every perspective except that of the 
patients. This exception bespeaks the human condition: if 
we are healthy, we may give due regard to meta-concep-
tions and assign importance to distributive justice and 
solidarity principles; if we are seriously ill, we are mainly 
interested in our own condition. Costs are relevant only 
to policy-makers, which explains why it is up to them to 
make unpopular decisions.
Enhancing the health status experienced by those who 
are already quite healthy is a legitimate policy objective. 
However, many countries pursue a much stronger pol-
icy goal of reducing the suffering of severely ill people. 
This emphasis is largely based on the idea that patients 
in bad health are in greater need. As such, need is one 
of the guiding principles of justice that are raised in aca-
demic discussions, along with maximizing population 
health and egalitarian principles that play a greater role 
in the area of economics and public health [23, 80, 81]. 
A well-known example of combining different principles 
in practice has been explored by Hadorn [82] in a study 
of the Oregon Health Services Commission, which drew 
up a package of healthcare services that should qualify 
for public funding. This procedure gives some weight to 
maximizing health (because relatively ineffective health-
care is not funded) and some weight to distributing in 
proportion to capacity to benefit (because relatively effec-
tive healthcare is funded even if it is not cost-effective).
Various procedures and principles have been put for-
ward to deal in a structured manner with the imperative 
to prioritize health interventions or programs. Most of 
these procedures and principles are rather academic. A 
few countries have a clear policy framework by which to 
evaluate (mostly new) health interventions. In the UK, 
under NICE, new drugs have been rejected for reim-
bursement. In the Netherlands, several drugs that are 
hardly cost-effective are nonetheless prescribed and 
reimbursed for other reasons.
In a survey of attitudes represented in the Swedish for-
mulary committees, Anell [83] discerned the five most 
important criteria for the establishment of clinical guide-
lines. Among these were three effectiveness parameters: 
therapeutic effects, adverse effect profile, and probability 
of patient adherence (e.g., drugs, rehabilitation, lifestyle). 
Another study examined the current health policy of 
about 40 countries and observed five criteria: effectivity, 
safety, level of evidence, severity of disease, and budget-
ary impact [20]. Safety is often mentioned as a separate 
criterion for evaluating health interventions, but in fact 
in most cases, formal safety and quality checks have been 
conducted for drugs and devices before they are certified 
to enter the market (e.g., European Medicine Agency). 
Similarly, ‘level of evidence’ is neither an argument nor a 
criterion but a precondition.
Conclusion
Many arguments and criteria seem to play a role in value 
judgments regarding health interventions. As they may 
interact which each other, we are dealing with a com-
plex system of different and even conflicting arguments 
and criteria. It seems that there is no practical, structured 
way to deal with these factors such that the results can 
rationally be applied to reimbursement decisions. Some 
methodological frameworks (e.g., multi-criteria decision 
analysis) are possible candidates for approaching this 
complex research question [84]. However, the number of 
optional criteria is very large, and we lack a limited set 
of criteria that take precedence under all conditions. An 
analytical framework based on axiomatic theory or math-
ematical models, such as multi-criteria decision making, 
would probably only serve a crude role in prioritizing 
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some distinct healthcare interventions. In the end, elab-
orate public discussion may be the most viable process 
facilitating societal consensus about health policy argu-
ments and criteria.
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